Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, and manage side effects of treatment.
The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.
Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 45 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.
Brain
A221101 (Alliance):
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme. (NCT01781468)
Breast
A011106 (ALLIANCE):
ALTernate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study (NCT01953588) Arm 1 open
A011202:
Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
ECOG-ACRIN EA1131:
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
ALLIANCE A011401:
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
S1207:
Ph III Rand, Placebo-Controlled Trial Evaluating Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Pts w/ High-Risk, Hormone Receptor-Positive & HER2/NEU Negative Breast Cancer
NRG-BR003:
Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
NSABP-B-55:
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
CTSU S1416:
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
A011104:
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
Gastrointestinal
N1048:
Ph II/III Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation Vs Preop Combined Modality Chemoradiation for Locally Advanced Rectal Ca Pts Undergoing Low Anterior Resection w/ Total Mesorectal Excision
NRG-GI002:
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)
A021502: Randomized Trial of Standard Chemotherapy Alone or
Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III
Colon Cancer and Deficient DNA Mismatch Repair
Genitourinary
NRG RTOG-0924:
Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Gynecological
NRG GOG-0238:
A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
NRG NRG-GY006:
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
NRG RTOG-0724:
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Head and Neck
WF 97115:
Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
Hematologic
NHLBI-MDS:
The National Myelodysplastic Syndromes (MDS) Study
E1A11:
Rand Ph III Trial of Bortezomib, LENalidomide & Dexamethasone (VRd) Vs. Carfilzomib, Lenalidomide & Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Lung
NRG-CC003:
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer **Temporarily closed to Accrual 10/13/17**
A151216:
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105, E4512, & EA5142**
A081105:
Rand, Double-Blind, Placebo-Controlled Study of Erlotinib or Placebo in Pts w/ Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC **Must be enrolled on screening trial A151216**
E4512:
Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**
EA5142:
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers **Must be enrolled on screening trial A151216**
Melanoma
Other
DCP-001:
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
S1609:
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
WF-10217: Work Ability in Young Adult Survivors (WAYS)
Symptom Management/Cancer Control
WF 97115:
Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
S1415CD:
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A221602: OlanzapineWith or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nauseaand Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):
A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Thyroid
